Investigational Drug Information for NB-001
✉ Email this page to a colleague
What is the drug development status for NB-001?
NB-001 is an investigational drug.
There have been 6 clinical trials for NB-001.
The most recent clinical trial was a Phase 3 trial, which was initiated on October 1st 2012.
The most common disease conditions in clinical trials are Herpes Labialis, Syndrome, and 22q11 Deletion Syndrome. The leading clinical trial sponsors are NanoBio Corporation, Danube Pharmaceuticals, Inc., and Nobias Therapeutics, Inc.
Summary for NB-001
| US Patents | 0 |
| International Patents | 0 |
| US Patent Applications | 10 |
| WIPO Patent Applications | 2 |
| Japanese Patent Applications | 3 |
| Clinical Trial Progress | Phase 3 (2012-10-01) |
| Vendors | 46 |
Recent Clinical Trials for NB-001
| Title | Sponsor | Phase |
|---|---|---|
| NB-001 in Children and Adolescents With 22q11 Deletion Syndrome | Nobias Therapeutics, Inc. | Phase 2 |
| NB-001 Treatment of Recurrent Herpes Labialis | NanoBio Corporation | Phase 3 |
| A Multicenter Study of NB-001 in the Treatment of Recurrent Herpes Labialis | NanoBio Corporation | Phase 3 |
Clinical Trial Summary for NB-001
Top disease conditions for NB-001
Top clinical trial sponsors for NB-001
US Patents for NB-001
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
